Vertex’s Cystic Fibrosis Therapy Expands to Younger Children, More Adults
Cystic Fibrosis, News
Vertex Pharmaceuticals Inc. recently confirmed that the European Commission has expanded the indication of Kalydeco® (ivacaftor) to two more groups of patients: children ages 2 to 5 with cystic fibrosis (CF) who have at least ... Read more